{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,25]],"date-time":"2026-03-25T20:00:29Z","timestamp":1774468829433,"version":"3.50.1"},"reference-count":21,"publisher":"BMJ","issue":"4","license":[{"start":{"date-parts":[[2023,12,19]],"date-time":"2023-12-19T00:00:00Z","timestamp":1702944000000},"content-version":"unspecified","delay-in-days":18,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"name":"Frauenhofer Institute for Translational Medicine and Pharmacology ITMP, Frankfurt am Main, Germany","award":["Not applicable"],"award-info":[{"award-number":["Not applicable"]}]},{"DOI":"10.13039\/501100023684","name":"Fraunhofer Cluster of Excellence for Immune-Mediated Diseases","doi-asserted-by":"crossref","award":["Not applicable"],"award-info":[{"award-number":["Not applicable"]}],"id":[{"id":"10.13039\/501100023684","id-type":"DOI","asserted-by":"crossref"}]},{"name":"LOEWE Zentrum Translational Medicine and Pharmacology","award":["Not applicable"],"award-info":[{"award-number":["Not applicable"]}]},{"DOI":"10.13039\/501100024879","name":"Janssen Cilag","doi-asserted-by":"crossref","award":["Not applicable"],"award-info":[{"award-number":["Not applicable"]}],"id":[{"id":"10.13039\/501100024879","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["RMD Open"],"accepted":{"date-parts":[[2023,10,2]]},"published-print":{"date-parts":[[2023,12]]},"abstract":"<jats:sec>\n                  <jats:title>Background<\/jats:title>\n                  <jats:p>The influence of sex on treatment outcomes during interleukin-12\/23 therapy in patients with psoriatic arthritis (PsA) has not been explored.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Objective<\/jats:title>\n                  <jats:p>To conduct exploratory post hoc analyses of sex-stratified data from the MUST trial, an investigator-initiated, multicentre, phase 3b study in which patients with active PsA initiating treatment with open-label ustekinumab were randomised to treatment with placebo or methotrexate (MTX).<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>We evaluated baseline characteristics, key treatment outcomes and adverse events stratified by sex, with a focus on outcomes that did not include erythrocyte sedimentation rate (ESR) as a component due to the known elevation of ESR in females.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>A total of 166 patients were treated with ustekinumab+MTX (37 female, 50 male) or ustekinumab+placebo (32 female, 47 male). At baseline, females had a significantly longer time since PsA diagnosis and greater impairment in physical function, but similar joint counts. At week 24, both females and males showed marked improvements to ustekinumab with or without MTX. Females generally had numerically reduced treatment responses compared with males, although differences did not achieve statistical significance. MTX did not show an overall effect on treatment outcomes, but was associated with faster enthesitis responses in males only. Adverse events were generally comparable, but females in the ustekinumab+MTX group had higher levels of gastrointestinal disorders.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusion<\/jats:title>\n                  <jats:p>Females and males with PsA had differences in baseline characteristics, treatment responses and adverse events during therapy. A better understanding of sex-based differences in PsA may help optimise treatment.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1136\/rmdopen-2023-003538","type":"journal-article","created":{"date-parts":[[2023,12,19]],"date-time":"2023-12-19T12:15:37Z","timestamp":1702988137000},"page":"e003538","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":5,"title":["Differences in treatment response between female and male psoriatic arthritis patients during IL-12\/23 therapy with or without methotrexate: post hoc analysis of results from the randomised MUST trial"],"prefix":"10.1136","volume":"9","clinical-trial-number":[{"clinical-trial-number":"nct03148860","registry":"10.18810\/clinical-trials-gov"}],"author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3579-5574","authenticated-orcid":false,"given":"Michaela","family":"Koehm","sequence":"first","affiliation":[{"name":"Division of Rheumatology, University Hospital Frankfurt, Goethe University, Frankfurt am Main, Germany"},{"name":"Fraunhofer Institute for Translational Medicine and Pharmacology ITMP, Frankfurt am Main, Germany"},{"name":"Fraunhofer Cluster of Excellence for Immune-Mediated Diseases CIMD, Frankfurt am Main, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2049-3204","authenticated-orcid":false,"given":"Ann C","family":"Foldenauer","sequence":"additional","affiliation":[{"name":"Fraunhofer Institute for Translational Medicine and Pharmacology ITMP, Frankfurt am Main, Germany"},{"name":"Fraunhofer Cluster of Excellence for Immune-Mediated Diseases CIMD, Frankfurt am Main, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tanja","family":"Rossmanith","sequence":"additional","affiliation":[{"name":"Fraunhofer Institute for Translational Medicine and Pharmacology ITMP, Frankfurt am Main, Germany"},{"name":"Fraunhofer Cluster of Excellence for Immune-Mediated Diseases CIMD, Frankfurt am Main, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Herbert","family":"Kellner","sequence":"additional","affiliation":[{"name":"Schwerpunktpraxis f\u00fcr Rheumatologie und Gastroenterologie und \u00c4rztlicher Leiter, Abteilung Rheumatologie, Krankenhaus Neuwittelsbach, Munchen, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5668-4497","authenticated-orcid":false,"given":"Uta","family":"Kiltz","sequence":"additional","affiliation":[{"name":"Rheumazentrum Ruhrgebiet, Herne, Germany"},{"name":"Ruhr University Bochum, Bochum, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7518-1131","authenticated-orcid":false,"given":"Gerd R","family":"Burmester","sequence":"additional","affiliation":[{"name":"Rheumatology and Clinical Immunology, Charit\u00e9 Universit\u00e4tsmedizin Berlin, Berlin, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6164-3980","authenticated-orcid":false,"given":"David M","family":"Kofler","sequence":"additional","affiliation":[{"name":"Clinical Immunology and Rheumatology, Department I of Internal Medicine, University Hospital Cologne, Cologne, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jan","family":"Brandt","sequence":"additional","affiliation":[{"name":"Rheumatologische Schwerpunktpraxis, Berlin, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7625-9612","authenticated-orcid":false,"given":"Stephanie","family":"Finzel","sequence":"additional","affiliation":[{"name":"Rheumatology and Clinical Immunology, University of Freiburg Medical Center, Freiburg, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7965-1273","authenticated-orcid":false,"given":"Raoul","family":"Bergner","sequence":"additional","affiliation":[{"name":"Medizinische Klinik A, Klinikum Ludwigshafen, Ludwigshafen, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maren","family":"Sieburg","sequence":"additional","affiliation":[{"name":"Rheumatologische Facharztpraxis, Magdeburg, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8750-7186","authenticated-orcid":false,"given":"Frank","family":"Behrens","sequence":"additional","affiliation":[{"name":"Division of Rheumatology, University Hospital Frankfurt, Goethe University, Frankfurt am Main, Germany"},{"name":"Fraunhofer Institute for Translational Medicine and Pharmacology ITMP, Frankfurt am Main, Germany"},{"name":"Fraunhofer Cluster of Excellence for Immune-Mediated Diseases CIMD, Frankfurt am Main, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"239","published-online":{"date-parts":[[2023,12,19]]},"reference":[{"key":"2025090312304618000_9.4.e003538.1","doi-asserted-by":"crossref","DOI":"10.1186\/s13293-020-00301-y","article-title":"The impact of sex and gender on Immunotherapy outcomes","volume":"11","author":"Klein","year":"2020","journal-title":"Biol Sex Differ"},{"key":"2025090312304618000_9.4.e003538.2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(20)31561-0"},{"key":"2025090312304618000_9.4.e003538.3","doi-asserted-by":"publisher","DOI":"10.3899\/jrheum.110548"},{"key":"2025090312304618000_9.4.e003538.4","doi-asserted-by":"crossref","first-page":"2162","DOI":"10.1093\/rheumatology\/kez188","article-title":"Predictors, demographics and frequency of sustained remission and low disease activity in anti-tumour necrosis factor-treated rheumatoid arthritis patients","volume":"58","author":"Hamann","year":"2019","journal-title":"Rheumatology (Oxford)"},{"key":"2025090312304618000_9.4.e003538.5","doi-asserted-by":"crossref","DOI":"10.1007\/s11926-018-0744-2","article-title":"Gender differences in axial Spondyloarthritis: women are not so lucky","volume":"20","author":"Rusman","year":"2018","journal-title":"Curr Rheumatol Rep"},{"key":"2025090312304618000_9.4.e003538.6","doi-asserted-by":"publisher","DOI":"10.3899\/jrheum.220386"},{"key":"2025090312304618000_9.4.e003538.7","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/key140"},{"key":"2025090312304618000_9.4.e003538.8","doi-asserted-by":"crossref","first-page":"1772","DOI":"10.1002\/acr.24090","article-title":"Determinants of patient-reported Psoriatic arthritis impact of disease: an analysis of the association with gender in 458 patients from 14 countries","volume":"72","author":"Orbai","year":"2020","journal-title":"Arthritis Care & Research"},{"key":"2025090312304618000_9.4.e003538.9","doi-asserted-by":"crossref","DOI":"10.1186\/s13075-021-02680-y","article-title":"Sex-specific differences and how to handle them in early Psoriatic arthritis","volume":"24","author":"Passia","year":"2022","journal-title":"Arthritis Res Ther"},{"key":"2025090312304618000_9.4.e003538.10","doi-asserted-by":"crossref","first-page":"e262","DOI":"10.1016\/S2665-9913(22)00008-X","article-title":"Comparison between Adalimumab introduction and methotrexate dose escalation in patients with inadequately controlled Psoriatic arthritis (CONTROL): a randomised, open-label, two-part, phase 4 study","volume":"4","author":"Coates","year":"2022","journal-title":"The Lancet Rheumatology"},{"key":"2025090312304618000_9.4.e003538.11","doi-asserted-by":"publisher","DOI":"10.3899\/jrheum.211037"},{"key":"2025090312304618000_9.4.e003538.12","doi-asserted-by":"publisher","DOI":"10.3899\/jrheum.220154"},{"key":"2025090312304618000_9.4.e003538.13","doi-asserted-by":"crossref","first-page":"919","DOI":"10.1007\/s40744-022-00445-w","article-title":"Responses to Ixekizumab in male and female patients with Psoriatic arthritis: results from two randomized, phase 3 clinical trials","volume":"9","author":"Eder","year":"2022","journal-title":"Rheumatol Ther"},{"key":"2025090312304618000_9.4.e003538.14","article-title":"Impact of patient characteristics, including sex, on the efficacy of Upadacitinib compared with Adalimumab in patients with Psoriatic arthritis","volume":"74","author":"Eder","year":"2022","journal-title":"Arthritis Rheumatol"},{"key":"2025090312304618000_9.4.e003538.15","doi-asserted-by":"crossref","DOI":"10.1136\/rmdopen-2022-002718","article-title":"Sex differences in the efficacy, safety and persistence of patients with Psoriatic arthritis treated with tofacitinib: a post-hoc analysis of phase 3 trials and long-term extension","volume":"9","author":"Eder","year":"2023","journal-title":"RMD Open"},{"key":"2025090312304618000_9.4.e003538.16","doi-asserted-by":"crossref","first-page":"3382","DOI":"10.1093\/rheumatology\/kead089","article-title":"Gender-specific differences in patients with Psoriatic arthritis receiving Ustekinumab or tumour necrosis factor inhibitor: real-world data","volume":"62","author":"Van Kuijk","year":"2023","journal-title":"Rheumatology"},{"key":"2025090312304618000_9.4.e003538.17","doi-asserted-by":"crossref","first-page":"e14","DOI":"10.1016\/S2665-9913(22)00329-0","article-title":"Methotrexate plus Ustekinumab versus Ustekinumab monotherapy in patients with active Psoriatic arthritis (MUST): a randomised, Multicentre, placebo-controlled, phase 3B, non-inferiority trial","volume":"5","author":"Koehm","year":"2023","journal-title":"Lancet Rheumatol"},{"key":"2025090312304618000_9.4.e003538.18","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0266816","article-title":"Sex difference in disease burden of inflammatory arthritis patients treated with tumor necrosis factor inhibitors as part of Standard care","volume":"17","author":"Michelsen","year":"2022","journal-title":"PLoS ONE"},{"key":"2025090312304618000_9.4.e003538.19","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2008.102053"},{"key":"2025090312304618000_9.4.e003538.20","doi-asserted-by":"crossref","first-page":"S64","DOI":"10.1002\/acr.20577","article-title":"Measures of Psoriatic arthritis","volume":"63","author":"Mease","year":"2011","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"2025090312304618000_9.4.e003538.21","first-page":"1003","article-title":"The effect of gender on methotrexate prescription attitudes in Italian rheumatoid arthritis patients: the MARI study","volume":"37","author":"Giusti","year":"2019","journal-title":"Clin Exp Rheumatol"}],"container-title":["RMD Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/rmdopen-2023-003538","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,3]],"date-time":"2025-09-03T19:30:54Z","timestamp":1756927854000},"score":1,"resource":{"primary":{"URL":"https:\/\/rmdopen.bmj.com\/lookup\/doi\/10.1136\/rmdopen-2023-003538"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,12]]},"references-count":21,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2023,12,19]]},"published-print":{"date-parts":[[2023,12]]}},"alternative-id":["10.1136\/rmdopen-2023-003538"],"URL":"https:\/\/doi.org\/10.1136\/rmdopen-2023-003538","relation":{},"ISSN":["2056-5933"],"issn-type":[{"value":"2056-5933","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,12]]}}}